PeriRx, LLC Covering all Bases During Its Greater New York Dental Meeting Debut
Company’s Launch of its SaliMark™ OSCC Salivary Test
for Oral Cancer
Includes Free CE Course, Free Industry Reception and
Free Test Kit
Broomall, PA – November 24, 2014 – PeriRx LLC, a premier developer of breakthrough, non-invasive, oral
diagnostic technology, will be making its national debut at booth #1506 during the
Greater New York Dental Meeting from Sunday, November 30th to Wednesday,
December 3rd at the Jacob K. Javits Convention Center in New York City.
“We’re
very excited to be making our official debut at the Greater New York Dental
Meeting,” said Stephen M. Swanick, CEO and founder of PeriRx, LLC. “We’re using
a variety of ways to engage with members of the dental community and tell them
about SaliMark™ OSCC, the most clinically-advanced salivary test for oral
cancer, which is scheduled to ship before the end of the year.”
Development of this simple-to-use,
painless and noninvasive test was based on the strong scientific foundation of
NIH-funded research with initial discovery and pre-validation work conducted by
Dr. David Wong of the University of California at Los Angeles. What’s more, more than a decade of National
Institute of Dental and Craniofacial Research and National Institute of Health-
supported research make SaliMark™ OSCC the world’s most
scientifically-validated molecular DNA biomarker test for oral squamous cell
carcinoma.
In addition to exhibiting at booth
#1506, PeriRx will be introducing SaliMark OSCC in the following ways:
·
Free CE
Course: “Salivary Testing for Early Diagnosis of Oral Cancer" (course code
#3240) will be given on Sunday November 30th, 2014 at 9am. Attendees
will receive $15.00 lunch voucher at the end of the course which can be used at
any Javits restaurant. Course presenters are Jack Martin, MD, Neil
Gottherer, DDS and Mark Cohen, DDS.
·
Free Industry Reception: This press conference for the entire industry will
feature some late-breaking research data presented by the PeriRx executive team
that further confirms the efficacy of SaliMark OSCC for early oral cancer
detection. Several other industry leaders are expected to say a few words
regarding the importance of these latest findings. This free event will take place on Monday,
December 1st from 3:00 - 4:00 PM at booth # 5430.
-more-
·
Free SaliMark OSCC Test Kit: Any dental practice owner who pre-registers and
creates a PeriRx online ordering account, will receive one free SaliMark test
Kit in order to get familiar with the test, the protocol and the lab results. Simply
visit http://perirxsecure.com/register.php to register your practice and set up an account.*
For
more information about PeriRx, LLC or its SaliMark OSCC salivary test for oral
cancer, visit www.PeriRx.com, call 610-544-3500 or send an email to info@PeriRx.com.
* Not
yet approved for sale in the state of New York. New York practice owners who
register online will be kept on file and notified immediately when SaliMark is
approved for sale and use in their state.
About
SaliMark™ OSCC
Development of this simple-to-use,
painless and noninvasive test was based on the strong scientific foundation of
NIH-funded research with initial discovery and pre-validation work conducted by
Dr. David Wong of the University of California at Los Angeles. The SaliMark OSCC test also has the distinction of
being the first of its kind assay in the world to aid in the identification and
early detection of oral lesions at the highest risk for cancer. Recently, the SaliMark OSCC test underwent a PRoBE (prospective-specimen-collection,
retrospective-blinded-evaluation) design study which is the most rigorous
biomarker validation available. In addition, PeriRx successfully completed a
validation of the mRNA markers at the University of Michigan, Michigan State University
and the St. Johns Providence Health System in Detroit.
About PeriRx LLC:
Based in Broomall, Pennsylvania, PeriRx
LLC is a premier developer of breakthrough, non-invasive, oral diagnostic
technology that will help clinical professionals detect and treat diseases sooner and
enhance the practice of wellness management.
The company was
founded in 2008 to explore, innovate, and develop novel therapeutics or devices
focused on the oral inflammatory/systemic connection. The PeriRx executive team
consists of CEO and founder Stephen M. Swanick, an entrepreneur and experienced
drug and device development professional; Dr. Neil Gottehrer, a practicing
dentist; and Dr. Jack Martin, a cardiologist.
PeriRx obtained its patented and patent-pending
technologies from inventor Dr. David Wong’s firm RNAmeTRIX and the Regents of
the University of California at Los Angeles. PeriRx and RNAmeTrix have ongoing
agreements which ensure the continuing research and development necessary to
advance product development from clinical trial, through regulatory approval,
and into commercialization.
Comments